TSE:4507Pharmaceuticals
How Shionogi’s Q1 2026 Earnings Jump and U.S. XOCOVA Launch Will Impact Shionogi (TSE:4507) Investors
Shionogi & Co., Ltd. has reported past first-quarter 2026 results showing sales of ¥163,310 million and net income of ¥97,696 million, while also beginning U.S. sales of its FDA-approved COVID-19 post-exposure prophylaxis drug, encitrelvir fumarate (XOCOVA).
This combination of sharply higher earnings and the launch of a first-in-class oral COVID-19 preventive therapy in the U.S. adds a new dimension to Shionogi’s portfolio and geographic reach.
We’ll now examine how Shionogi’s U.S. launch...